Merck, a leading science and technology company ... More mature data for PROCEADE-CRC-01 and details on the design for the PROCEADE-PanTumor study investigating precemtabart tocentecan in patients ...

Despite a strong cash position and no debt, my NPV model shows NUVB is fairly valued or overvalued at $1.73. Click here to ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

This is the online version of our BIO 2025 newsletter. Get more BIO updates directly to your inbox by signing up here, and ...

That challenge, of finding or building good, usable data sets, is also one of the biggest differentiators in an increasingly ...

The Trump administration has escalated its tech crackdown on China with a sweeping ban on Electronic Design Automation (EDA) ...

At the crossroads of innovation and equity, Josette Gbemudu and Merck are helping rewrite the narrative for breast cancer with digital tools.

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

Merck, a leading science and technology company ... The study features a unique design across two lupus cohorts, including both patients with active SLE and CLE. Cohort A focused on patients ...

Merck & Co. Inc., a global health care company working to deliver ... and a challenging path taking us from the first design phase of the processing line right up to commissioning, training and ...